Trusted Resources: News & Meetings
Latest announcements and gatherings
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, 2021 – ResearchAndMarkets.com
The “Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. The clinical trial report provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome).
Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
BookmarkRelated Content
-
Evidence of Treatment Benefits in Patients With Mucopolysaccharidosis Type I-Hurler in Long-Term Follow-Up Using a N...We developed a brain and spine magnetic ...
-
Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis Type IMusculoskeletal findings in MPS can prog...
-
Fetal Therapies and Trials for Lysosomal Storage Diseases: A Survey of Attitudes of Parents and PatientsLysosomal storage diseases (LSDs) are in...
-
A Guide to Understanding MPS I (Hurler, Hurler-Scheie, and Scheie Syndromes)What Is MPS I? Mucopolysaccharidosis I (...
-
Mucopolysacharidosis Type I Presenting as Bipolar Affective Disorder: A Case ReportMucopolysacharidosis type I is a multisy...
-
Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in KidsGene therapy might soon offer a new opti...
-
Experimental MPS 1 Therapy Shows Biomarker Activity, Improved FunctionREGENXBIO presented results from its ong...
Powered by
